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Abstract: Few fiber supplements have been studied for physiological effectiveness. The 
effects of native banana starch (NBS) and soy milk (control) on body weight and insulin 
sensitivity in obese type 2 diabetics were compared using a blind within-subject crossover 
design. Subjects undertook two phases of 4-week supplementation either with NBS or soy 
milk. Patients on NBS lost more body weight than when they were on control treatment. 
Plasma  insulin  and  HOMA-I  were  reduced  after  NBS  consumption,  compared  with 
baseline  levels,  but  not  significantly  when  compared  to  the  control  treatment.  Results 
support the use of NBS as part of dietary fiber supplementation.  
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1. Introduction  
The number of people with diabetes worldwide is projected to rise from 171 million in 2000 to 366 
million by 2030 [1]. This expectancy is associated with the increasing prevalence of overweight and 
obesity. Obesity and type 2 diabetes frequently occur together, and statistics show that 60–90% of type 
2 diabetics are or have been obese [2,3]. Insulin resistance (IR) is the key mechanism unifying obesity 
and type 2 diabetes. IR is characterized as the tissues inability to take up glucose in response to insulin. 
In the course of months or years, IR is accompanied by the increase in β-cell insulin secretion and by 
different complications known as the insulin resistance syndrome which is associated to dyslipidemia, 
hypertension, hyperglycemia and cardiovascular disease [4]. 
When discussing strategies for metabolic control and weight loss in diabetic patients, necessarily 
life style modifications should be considered [5]. From the point of view of dietary habits, it has been 
reported that subjects with higher whole-grain intake present lower insulin concentrations [6,7], while 
low  dietary  fiber  consumption  is  linked  to  a  reduction  in  insulin  sensitivity  [8].  The  Institute  of 
Medicine  (IOM)  has  defined  dietary  fiber  as  the  nondigestible  carbohydrates  and  lignin  that  are 
intrinsic  and  intact  in  plants  whereas  functional  fiber  consists  of  the  isolated  nondigestible 
carbohydrates  to  have  beneficial  physiological  effects  in  human  beings  [9].  Accordingly,  resistant 
starch  (RS)  could  be  considered  a  functional  fiber  by  its  indigestible  nature  and  beneficial 
physiological effects [10]. RS escapes digestion in the human small intestine and is fermented in the 
colon with production of metabolically active short chain fatty acids (SCFA), [11]. Banana resistant 
starch belongs  to  a RS2  class which consists of native starch granules that are highly resistant to 
digestion by α-amylases [12]. The native banana starch (NBS) used in this study was obtained from 
unripe banana (Musa Cavendish AAA) which is cheap and produced in high levels in Tabasco State, 
Mexico. Starches from different sources have diverse structures and consequently different resistance 
to enzymatic hydrolysis. The grade of resistance to digestibility among different starches generally 
correlates to their amylose content. Previous studies from our group have found in this banana variety a 
high amylose-content and a high resistance to digestibility. Moreover a reduced glycemic and insulinic 
response after NBS consumption in healthy and diabetic subjects was demonstrated [13]. In the present 
study, we hypothesized that NBS may reduce body weight and increase insulin sensitivity in obese type 
2 diabetics.  
2. Material and Methods 
2.1. Patients 
The experimental protocol was approved by the ethical committee from the Hospital General de 
Zona 46 from the Instituto Mexicano del Seguro Social (IMSS). A total of 30 patients with type 2 
diabetes  according  to  the  WHO  criteria,  were  recruited  from  subjects  attending  the Hospital.  The 
purpose  of  the  study  was  explained  to  the  participants  and  they  gave  written  informed  consent. Int. J. Environ. Res. Public Health 2010, 7                 
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Subjects  were  included  if  they  had  less  than  10  years  of  type  2  diabetes  diagnosis,  were  obese 
according to the WHO criterion (Body Mass Index, BMI > 30), were between 40 to 60 years of age, 
had  maintained  stable  weight  during  three  months  prior  to  experimentation  and  were  under  the 
attention  of  a  health  care  provider  from  the  IMSS.  Study  participation  did  not  limit  the  medical 
management  they  were  provided.  Subjects  not  included  in  this  study  were  BMI  <  30,  with 
complications  such  as  nephropathy  or  hepatic  diseases,  on  psychiatric  treatments,  receiving 
inmmunosupressors  or  body  reducers,  with  a  smoking  or  alcoholic  history  and  receiving  insulin 
treatments. Seventeen subjects were taking oral hypoglycemic agents, 11 were on biguanides alone and 
six were taking both sulfonylureas and biguanides. A criterion for exclusion was if they modified their 
medical treatment during the study. All participants were examined for anthropometric measurements 
including height, body weight, waist and hip circumferences. Other determinations were blood pressure 
and fat percentage. A 24 h food record was performed by a nutritionist using a validated survey.  
2.2. Study Design 
A cross over design with two experimental periods of 4 weeks was used to compare the effects of 
NBS supplementation with those of soya milk. Thirty patients met the eligibility criteria, complete 
baseline testing and were randomly assigned to two groups of fifteen subjects to receive either 24 g of 
NBS dissolved in 240 mL of water per day or 24 g/day of soy milk dissolved in the same volume of 
water for 4 weeks. After this period all data measures were collected, groups cross over to the alternate 
treatment group for an additional 4 weeks period after which final measures were taken at 8 weeks. 
There was no wash-out period between the interventions. All participants received both supplements, 
and on the two phases of the experiment they were instructed not to modify their diet and exercise 
habits. Two women, one of each group, withdrew during the first phase due to personal reasons. The 
treatment compliance was supervised every week through clinical interviews in order to check the 
amount of consumed supplement and determine their body weight, side effects or adverse events. 
Further information was obtained from the patients through telephone interviews.  
2.3. Material and Experimental Procedures 
The NBS was provided by the Centro de Investigaciones Agropecuarias of the Universidad Juarez 
Autonoma de Tabasco. NBS was obtained from unripe (green) banana (Musa cavendish AAA) with a 
physiological age of 15 weeks obtained from a packing plant situated on Km 43.5 of the Villahermosa-
Teapa road. The NBS was isolated by a previously described procedure [14]. Briefly, after washing the 
bananas  were peeled, cut into 5–6 cm
3 pieces, immediately rinsed in citric acid solution and then 
macerated at low speed in an industrial blender for 2 min. The homogenate was consecutively sieved 
through screens (30, 80 and 100 US mesh) and washed with distilled water; it was then centrifuged at 
10,000 rpm. Sediment was further purified by washing and centrifugation. The white starch sediment 
was dried in a convection oven at 40–45 ºC , passed through a 100 mesh screen and stored at room 
temperature in sealed glass jars. The dry basis yield of starch was 60%. The proximate analysis was as 
follows: 3.4% of moisture content, 1.88% protein, 0.4281% fat and 0.78% ash (AOAC recommended 
methods 14.003, 14.057, 14.059 and 14.006). Water activity (aw) of NBS was measured using the 
Aqualab (Decagon) equipment and gave a result of 0.59.  Int. J. Environ. Res. Public Health 2010, 7                 
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The  determination  of  resistance  in  the  banana  starch  flour  was  carried  out  according  to  the 
enzymatic method of Goñ i et al. [15] as follow: protein residues in the powder were hydrolyzed with 
pepsin under acidic conditions (pH 1.5, 40 ºC , 1 h). Then, tris-maleate buffer was added and the 
mixture incubated with α-amylase (37 ºC , pH 6.9, 16 h) to hydrolyze digestible starch. The hydrolysis 
product was eliminated and the non-digestible starch was recovered by centrifugation. After dispersing 
under alkaline conditions (2M KOH) to solubilize NBS, it was incubated with amyloglucosidase under 
acid  conditions.  Glucose  concentration  was  determined  by  an  enzymatic-colorimetric  method. 
Resistance starch concentration of NBS was measured as percentage on a dry weight basis. A 34% of 
resistance was found by this method. Twenty four grams of native banana starch contained 8.16 g of 
resistant starch.  
Soy milk powder was purchased as the commercial product Soyapac produced from whole soy 
beans  by  Colpac  (Km  3,  Navojoa-Sonora  road,  Huatabampo,  Navojoa,  Sonora,  Mexico)  with  a 
nutritional content of 46.2% of fat, 30.8% carbohydrates, 20.5% protein.  
2.4. Clinical Laboratory Assays 
Blood samples were obtained by trained personal at the onset of the study and then after 4 and 8 
weeks. Blood serum samples were immediately frozen and conserved at −70 ºC  until biochemical 
determinations.  Sera  samples  were  analyzed  for  glucose,  cholesterol,  LDL,  HDL-cholesterol  and 
triglycerides  by  using  an ADVIA® 1200 Chemistry System  from  Siemens  Healthcare Diagnostics 
(intra-assay  coefficient  of  variation:  glucose  3.5%,  cholesterol  4.9%,  LDL  5.2%,  HDL-cholesterol 
6.1%, triglycerides 5.2%). Insulin was determined according to the method for AxSYM of Abbott 
based  on  a  microassay  microparticle  inmunoenzymatic  assay.  To  prevent  enzymatic  insulin 
degradation special care was taken to avoid hemolysis during the blood sampling and manipulation.  
Glycated hemoglobin (HbA1c) was measured by a turbidimetric inmunoinhibition method according 
to Beckman Coulter for a Synchron CX7 Clinical System. Insulin resistance was estimated according 
to the Homeostasis Model Assessment (HOMA) which was calculated by the product of the fasting 
concentrations of glucose (mg/dL) and insulin (μU/mL) divided by 405 [16].  
2.5. Statistical Analysis 
The  characteristics  of  the  subjects  are  presented  as  mean  ±   SD  or  median  and  percentiles. 
D’Agostino-Pearson normality test was performed to assess if the data were consistent with a Gaussian 
distribution. Changes of endpoints after treatments at 4 weeks were expressed as change from baseline 
(1st treatment) and for the 2nd treatment baseline was considered the endpoint of the 1st treatment. 
Student’s t test was used for comparing variables with normal distribution or Mann-Whitney test for 
data from a nongaussian distribution. With the purpose to investigate the possible carry-over effects 
during the second treatment period we carried out the statistical analysis on the first period as a parallel 
design. Statistical significance was defined as p < 0.05. Calculation was performed using GraphPAD 
PRIZMA software version 5.01. Int. J. Environ. Res. Public Health 2010, 7                 
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3. Results  
3.1. Characteristics of the Patients 
The baseline characteristics of 28 patients who completed the treatments are shown on Table 1. A 
great percentage of the obese subjects were women (85.7%), most of them housewives, 96% of them 
had waist circumference values over 88 cm, with a high waist-to-hip ratios, 0.873 (0.85, 0.91; median 
and 25th,75th percentiles). Half of the male subjects had WHR values higher than 0.95. Poor glycemic 
control was observed in most patients, despite their medical management, 85% had glucose values 
over 126 mg/dL and 42% had HbA1c percentage higher than 7.0. Cholesterol levels were higher than 
200 mg/dL in 60.7% of the participants and 76% had triglycerides over 160 mg/dL. In addition, 94% of 
patients had a sedentary lifestyle and most of them lived in rural areas and had both a low academic 
and socioeconomic status.  
Table 1. Characteristics of the type 2 diabetic patients at baseline. Data are means ±  SD or 
median (25th ,75th percentiles). HbA1c (Glycated hemoglobin), BMI (Body Mass Index), 
HDL (High Density Lipoproteins).
a Calculated by electrical impedance (Tanita BF-350).  
Characteristics  Value 
Men/Women (n = 28)  4/24 
Age (y)  51.7  5.6 
Body weight (Kg)  79.00  16.63 
Height (m)
  1.50  0.10 
BMI ( Kg /m
2)  34.89 ± 2.32 
Fasting glycemia (mg/dL)   145.94  104.17 
Fasting insulin (µU/mL)  14.1 (8.6, 20.30) 
Waist circumference (cm)  102.5 ±  9.61 
Waist to hip ratio (WHR)   0.87 (0.85, 0.91)  
Body fat (%)
a   40.93  5.11 
HbA1c (%)  6.4 (4.5, 9.6) 
Total cholesterol (mg/dL)  205.5 (187.8, 251.5) 
HDL-cholesterol (mg/dL)  42.07  8.60 
Triglycerides (mg/dL)  227 (165.3, 311.5) 
3.2. Dietary Treatment and Compliance 
Compliance with the diet and treatment was excellent (91% for NBS and 93% for control group). 
No significant differences in compliance were observed between the supplemented groups. The NBS 
preparation was in general well tolerated, although three patients from each group reported flatulence, 
increased number of evacuations and soft feces during the first week of the experimental period. No 
other side effects or adverse events were reported by any of the participants. 
3.3. Body Weight 
Body  weight  and  BMI  were  significantly  reduced  after  NBS  supplementation  compared  to  the 
control group (p = 0.0021 and p < 0.0001, respectively). The NBS groups lost 1.568 kg after 4 weeks Int. J. Environ. Res. Public Health 2010, 7                 
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of treatment and the control group lost only 300 g (Table 2). When a statistical analysis of the first 
period was carried out, results were similar, body weight was reduced after NBS in comparison with 
baseline levels and when compared to the control treatment (p = 0.0004 and p = 0.0135, respectively). 
3.4. Glycemic Control and Insulin Resistance 
No significant changes were observed in glycemia and HbA1c levels across either treatments or 
between treatments. However, fasting insulin concentration was significantly reduced in NBS group in 
comparison  with  baseline  values  (p  =  0.009),  but  not  significant  when  compared  to  the  control 
treatment (Table 2). A small and non-significant reduction on insulin levels was observed after control 
treatment (p = 0.087). As it was expected, insulin sensitivity measured by HOMA was significantly 
increased after NBS treatment versus baseline values. However, it was not significant when compared 
to the control treatment (Table 2).  
Table 2. Comparison of responses after consuming NBS or soy milk. Changes of endpoints 
after treatments at 4 weeks were expressed as change from baseline (1st treatment) and for 
the 2nd treatment the endpoint of the 1st treatment was used. Data are median (25th, 75th 
percentiles); Mann-Whitney test was used for intergroup comparisons.  
  NBS  CT  P value 
Body weight (Kg)  −1.2 (−1.95, −0.65)**  0.1 (−1.2, 0.7)  0.002 
BMI (Kg/m
2)  −0.59 (−0.85,−0.29)***  0.09 (−0.14, 0.37)  < 0.0001 
Fasting glycemia (mg/dL)  −2.0 (−43, 39.50)  1.0 (−15.75, 19.25)  0.796 
Fasting insulin (µU/mL)  −2.9 (−6.5, −0.8)**  −1.1(−4.9,0.0)  0.420 
HOMA−IR  2.21 (0.59, 3.36)*  1.12 (0.30, 2.93)  0.436 
Waist−to−hip−ratio  −0.00 (−4.9, 1.36)  1.13 (−2.48, 5.92)  0.048 
Body fat (%)  0.0 (−1.0, 0.0)  0.0 (0.0, 0.0)  0.442 
HbA1c (%)  −0.2 (−0.7, 0.15)  −0.1 (−0.6, 0.4)  0.840 
Total cholesterol (mg/dL)  0.5 (−18.75, 13.75)  2.0 (−17.5, 11.50)  0.781 
HDL−cholesterol (mg/dL)  0.0 (−3.25,2.75)  2.0 (−5.0, 6.0)  0.3395 
Triglycerides (mg/dL)  25.0 (−36.5, 58)  −40.0 (−76.0, 16.0)*  0.012 
Calcium (mg/dL)  −0.10 (−0.20, 0.20)  0.0 (−0.42, 0.30)  0.755 
Phosphates (mg/dL)  0.10 (−0.25, 0.20)  −0.10 (−0.42, 0.05)  0.111 
Statistical differences within group: *p < 0.05, **p < 0.01, ***p < 0.0001. NBS = Native Banana 
Starch, CT = Control group (Soy milk). 
 
The intragroup and intergroup differences for glycemia, insulin and HOMA-I variables were similar 
when a statistical analysis of the first period was carried out.  
3.5. Lipid Metabolism and Other Parameters 
There  were  no  significant  effects  of  NBS  intake  on  fasting  triglycerides,  cholesterol  levels,  
HDL-cholesterol, LDL-cholesterol and fat body percentage. However, unexpectedly control treatment 
(soy milk) reduced serum triglycerides versus baseline values (p < 0.05, Mann-Whitney) and this effect 
was higher than the one observed in the NBS group (Mann-Whitney, p = 0.0121). No changes across Int. J. Environ. Res. Public Health 2010, 7                 
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either  treatment  or  between  treatments  were  observed  on  calcium,  phosphate  and  hematological 
markers such as white blood cells, platelets and other indexes (not included in Table 2). 
 
4. Discussion 
 
In this study we have shown that NBS (24 g per day during 4 weeks) significantly lowers body 
weight and increases insulin sensitivity. Although there are reports on the beneficial effect of RS on the 
glycemic  and  insulin  responses,  there  are  no  studies  considering  the  effects  of  banana  starch  on 
diabetic obese subjects. Different studies have confirmed the beneficial effects of RS as prebiotic, 
hypocholesterolemiant,  having  hypoglycemic  effects,  inhibiting  fat  accumulation,  and  reducing  
gall stones [10]. 
This study was performed administering by NBS 24 g/day during 4 weeks mimicking the amount 
used by other groups and considering results from previous estimations obtained through food records 
which was 12 g/d of fiber consumption in subjects of this region. According to the current data, diets 
providing 30 to  50 g fiber  per day from  whole food sources produce lower serum glucose levels 
compared to a low-dietary fiber. Moreover, Dietary Reference Intakes recommend consumption of 25 g 
dietary fiber for adult women and 38 g for adult men, based on epidemiologic studies [9].  
Although the body weight modification (1.56 Kg) could be considered small from the clinical point 
of view, it must be highlighted that participants did not change their diet and exercise habits during the 
experimentation period. In a review of many studies on the effect of dietary fiber on hunger and body 
composition in healthy individuals, it is reported that the average effect of 14 g/fiber supplementation 
per day results in a 10% decrease in energy intake and a weight loss of 1.9 Kg through about 3.8 
months of intervention. Moreover, obese individuals exhibited greater reduction on body weight in 
comparison with lean people [17]. Comparison between studies however should be considered with 
caution due to differences between subjects’ health status and fiber source.  
The  mechanism  by  which  fiber  sources  lower  body  weight  has  been  focused  on  its  effects  to 
decrease food intake and promote satiation and/or satiety. Satiation is the satisfaction of appetite during 
feeding that marks the end of eating and satiety is the inhibition of hunger as a result of having eaten. 
Some studies support that increased fiber intake decreases hunger, provides a feeling of fullness and 
plays  a  role  in  the  control  of  energy  balance  [18].  On  the  other  hand,  body  weight  reduction  is 
associated with an increase in insulin sensitivity. This association is explained by the reduced demand 
on insulin production and secretion from the β-cells after losing weight. In this study, however, the 
small reduction on body weight after NBS might not be enough to modify the insulin demand. A better 
explanation is the reduced glycemic and insulinic responses induced by the NBS administration, as we 
have found in previous experiments after a NBS-single oral administration to healthy and diabetic 
subjects [13]. The chronic administration of NBS during 4 weeks might produce long-term effects 
which could reduce fasting insulin levels and insulin resistance on these subjects. Some authors have 
reported  lower  postprandial  glucose  and  insulin  response  after  resistant  starch  (high-amylose  corn 
starch) supplementation to normal and overweight subjects [19]. Other reports established a reduction 
on  insulin  resistance  measured  with  the  hyperglycemic-euglycemic  clamp  when  using  type  II  RS  Int. J. Environ. Res. Public Health 2010, 7                 
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(Hi-Maize 260) 30 g/day during 4 weeks [20]. In contrast, others have not found body weight reduction 
or fasting insulin changes after resistant corn starch 24 g/day for 21 days in obese subjects [21].  
This study was not designed to investigate the biochemical mechanism of action. However, other 
groups  have  informed  about  the  short  chain  fatty  acids  (SCFAs)  and  ghrelin  participation  in  this 
process. SCFAs were found increased in peripheral blood and their uptake index was augmented into 
skeletal muscle and adipose tissue after resistant starch administration [21]. These substances have also 
been shown to inhibit adipose tissue lipolysis in vivo [22]. In addition, SCFAs augmentation has been 
shown to potentially increment the expression of functional proteins within the intestine because of its 
ability to mediate the release of glucagon-like-peptide 2 [23,24]. Another possible mechanism is the 
increased ghrelin hormone peripheral concentration after resistant starch. Ghrelin elevation in plasma 
has been linked to increased insulin sensitivity in numerous studies [25]. In addition, ghrelin inhibits 
lipolysis  and  stimulates  both  lipogenesis  and  the  expression  of  peroxisome  proliferator  activated 
receptor γ in vitro (PPARγ) [26].  
Limitations of the study design are its relative short duration and the lack of a wash-out period 
between treatments. It is evident that a residual effect of the first phase could have biased the estimate 
of treatment effect. However, after the statistical analysis on the first period as a parallel design, the 
results from the cross-over analysis were corroborated. 
The lack of intergroup difference on insulin and HOMA-I could be partially explained by a soy milk 
small (not significant) lowering effect on both body weight and fast insulin concentration. Indeed, 
several studies have found beneficial effects of soy milk consumption on the glycemia homeostasis. 
Some authors reported that soy protein consumption lowered plasma insulin levels when compared to 
casein in rats [27]. Others have shown that soy phytoestrogens reduce insulin resistance improving 
glycemia control in postmenopausal women with type 2 diabetes [28].  
No effect of NBS on lipid metabolism was observed in the present study. In contrast, soy milk 
supplementation reduced serum triglycerides. We do not have an exact explanation for these findings, 
however, the beneficial effect of soy milk supplementation on lipid metabolism is well documented in 
rodents and humans [29-31].  
5. Conclusions 
In this study we have demonstrated that NBS 24 g/day during 4 weeks lowers body weight and 
increases insulin sensitivity in a group of obese type 2 diabetics. NBS supplementation could be a 
cheap alternative to reduce body weight and improve glucose homeostasis on subjects with insulin 
resistance. Further long-term studies with larger sample size on high risk subjects are recommended.  
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